A Phase 1 study of GDC‐0134, a dual leucine zipper kinase inhibitor, in ALS
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Clinical and Translational Neurology"
DOI: 10.1002/acn3.51491
Abstract: Dual leucine zipper kinase (DLK), which regulates the c‐Jun N‐terminal kinase pathway involved in axon degeneration and apoptosis following neuronal injury, is a potential therapeutic target in amyotrophic lateral sclerosis (ALS). This first‐in‐human study investigated… read more here.
Keywords: dual leucine; zipper kinase; kinase; gdc 0134 ... See more keywords